HOME >> MEDICINE >> NEWS
UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of todays most promising anticancer drugs and thereby increase their effectiveness.

The poor solubility of anticancer drugs is one of the major problems in cancer therapy because the drugs require the addition of solvents in order to be easily absorbed into cancer cells. Unfortunately, these solvents not only dilute the potency of the drugs but create toxicity as well.

In a paper scheduled to be published in the nanoscience journal Small in June, researchers from UCLAs California NanoSystems Institute and Jonsson Cancer Center report a novel approach using silica-based nanoparticles to deliver the anticancer drug camptothecin and other water-insoluble drugs into human cancer cells.

The study is led by Fuyu Tamanoi, UCLA professor of microbiology, immunology and molecular genetics and director of the Jonsson Cancer Centers Signal Transduction and Therapeutics Program Area, and Jeffrey Zink, UCLA professor of chemistry and biochemistry.

Tamanoi and Zink devised a method for incorporating the representative hydrophobic anticancer drug camptothecin into the pores of fluorescent mesoporous silica nanoparticles and delivering the particles into a variety of human cancer cells to induce cell death. The results suggest that the mesoporous silica nanoparticles might be used as a vehicle to overcome the insolubility problem of many anticancer drugs.

Silica nanomaterials show promise for delivering camptothecin and other water-insoluble drugs, Tamanoi said. We have successfully loaded hydrophobic anticancer drugs into mesoporous nanoparticles and delivered them into human cancer cells to induce cell death.

The beauty of our findings is that these nanoparticles are biocompatible, contain tubular pores and are relatively easy to modify, Zink said. A
'"/>

Contact: Jennifer Marcus
jmarcus@cnsi.ucla.edu
310-267-4839
University of California - Los Angeles
6-Jun-2007


Page: 1 2

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. Cedars-Sinai researchers present new endocrine findings at 2 international conferences

Post Your Comments:
(Date:6/18/2013)... DC (PRWEB) June 18, 2013 The ... Department of State and the U.S. President’s Emergency Plan ... anniversary and celebrate significant new milestones in the global ... State John Kerry announced that as of June 2013, ... to PEPFAR support. Since PEPFAR’s inception in 2003, ...
(Date:6/18/2013)... 2013 Two months ago, Suyima Torres, 28, ... for a second session of a silicone treatment for gluteus ... treatment was allegedly performed by a mystery Venezuelan doctor in ... According to Dr. Bernabe Vazquez of Bayshore Cosmetic Surgery ... from doctor’s who are not board certified is more common ...
(Date:6/18/2013)... A new $119 million industry is ... industry is redefining the way consumers get their seafood. ... personal culinary chefs on the Emerald Coast panhandle of ... seafood and the promising industry of aquaculture. , The ... consumers strive to fully partake in the effort, especially ...
(Date:6/18/2013)... York (PRWEB) June 18, 2013 As ... state and federal court, a new report has revealed that ... 70,000 U.S. Food & Drug Administration (FDA) adverse event reports ... NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena users have reported ... more than 1,300 have reportedly experienced uterine perforations due to ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... Sinai Medical Center to its “Best Doctors” list, up ... in New York City. The new issue also lists 52 ... network, which continues on a strategic growth trajectory. The “Best ... physicians, appears in the June 24 print issue and is ...
Breaking Medicine News(10 mins):Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3Health News:New $119 Million Industry Swimming Up the East Coast 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...
(Date:6/18/2013)... MINNEAPOLIS , June 18, 2013 ... while being highly portable and lightweight. Simultaneously, circuitry ... and the processing speed to which it performs ... both medical electronics and military equipment, such as ... lightweight. Omnetics, micro-circular and nano-circular connectors include custom ...
(Date:6/18/2013)... SYDNEY, Australia And EMERYVILLE, ... Adamas Pharmaceuticals, Inc. presented final results today from ... HCl extended release) capsules demonstrating a statistically significant ... change from baseline at week 8 versus placebo ... is Adamas, investigational extended-release formulation of amantadine intended ...
Breaking Medicine Technology:Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6
Cached News: